Berberine-loaded PLGA Nanoparticles Alleviate Ulcerative Colitis by Targeting IL-6/IL-6R Axis

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 Oct 25

PMID 39448992

Authors

Chao Liu

Qiming Gong

Wanning Liu

Yihan Zhao

Xinhao Yan

Tao Yang

Affiliations

Soon will be listed here.

Abstract

Aims: The present study aims to develop a nano-delivery system that encapsulates berberine (BBR) into PLGA-based nanoparticles (BPL-NPs), to treat ulcerative colitis (UC). Furthermore, the therapeutic efficacy and molecular targeting mechanisms of BPL-NPs in the management of UC are thoroughly examined.

Methods: Emulsion solvent-driven methods were used to self-assemble BBR and PLGA into nanoparticles, resulting in the development of the nano-delivery system (BPL-NPs). The therapeutic effectiveness of BPL-NPs was evaluated using a dextran sulfate sodium (DSS)-induced model of ulcerative colitis in mice and a lipopolysaccharide (LPS)-induced model of inflammation in THP-1 macrophages. The interaction between Mφs and NCM-460 cells was investigated using a co-culture system. The molecular targeting ability of BPL-NPs in the treatment of UC was validated through in vitro as well as in vivo experiments.

Results: The BPL-NPs demonstrated a particle size of 184 ± 22.4 nm, enhanced dispersibility in deionized water, and a notable encapsulation efficiency of 31.1 ± 0.2%. The use of BPL-NPs clearly improved the clinical symptoms and pathological changes associated with UC in mice while also ensuring minimal toxicity. In addition, BPL-NPs improved intestinal epithelial cell apoptosis and enhanced the function of the intestinal barrier by inhibiting M1 Mφs infiltration and IL-6 signaling pathway in mice with UC. Furthermore, the BPL-NPs were found to selectively target the IL-6/IL-6R axis during the M1 Mφs-induced apoptosis of NCM460 cells.

Conclusion: The BPL-NPs were confirmed to harbor anti-inflammatory effects both in vitro and in vivo, along with enhanced water solubility and bioactivity. In addition, the precise targeting of the IL-6/IL-6R axis was confirmed as the mechanism by which the BPL-NPs exerted therapeutic effects in UC, as demonstrated in both in vitro as well as in vivo studies.

References

Zhou Y, Yang M, Yan X, Zhang L, Lu N, Ma Y . Oral Nanotherapeutics of Andrographolide/Carbon Monoxide Donor for Synergistically Anti-inflammatory and Pro-resolving Treatment of Ulcerative Colitis. ACS Appl Mater Interfaces. 2023; 15(30):36061-36075. DOI: 10.1021/acsami.3c09342. View

Li K, Strauss R, Ouahed J, Chan D, Telesco S, Shouval D . Molecular Comparison of Adult and Pediatric Ulcerative Colitis Indicates Broad Similarity of Molecular Pathways in Disease Tissue. J Pediatr Gastroenterol Nutr. 2018; 67(1):45-52. DOI: 10.1097/MPG.0000000000001898. View

Im K, Mareninov S, Diaz M, Yong W . An Introduction to Performing Immunofluorescence Staining. Methods Mol Biol. 2018; 1897:299-311. PMC: 6918834. DOI: 10.1007/978-1-4939-8935-5_26. View

Deng S, Yang Y, Cheng X, Li W, Cai J . Synthesis, Spectroscopic Study and Radical Scavenging Activity of Kaempferol Derivatives: Enhanced Water Solubility and Antioxidant Activity. Int J Mol Sci. 2019; 20(4). PMC: 6412309. DOI: 10.3390/ijms20040975. View

Yang T, Ma X, Wang R, Liu H, Wei S, Jing M . Berberine inhibits IFN-γ signaling pathway in DSS-induced ulcerative colitis. Saudi Pharm J. 2022; 30(6):764-778. PMC: 9257906. DOI: 10.1016/j.jsps.2022.03.015. View

Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T . Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021; 56(6):489-526. PMC: 8137635. DOI: 10.1007/s00535-021-01784-1. View

Ben-Horin S, Har-Noy O, Katsanos K, Roblin X, Chen M, Gao X . Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2022; 20(12):2868-2875.e1. DOI: 10.1016/j.cgh.2022.02.055. View

Zhang Q, Chen L, Yang H, Fang Y, Wang S, Wang M . GPR84 signaling promotes intestinal mucosal inflammation via enhancing NLRP3 inflammasome activation in macrophages. Acta Pharmacol Sin. 2021; 43(8):2042-2054. PMC: 9343429. DOI: 10.1038/s41401-021-00825-y. View

Du L, Ha C . Epidemiology and Pathogenesis of Ulcerative Colitis. Gastroenterol Clin North Am. 2020; 49(4):643-654. DOI: 10.1016/j.gtc.2020.07.005. View

10.

Wu M, Wang Q, Huang B, Mai C, Wang C, Wang T . Dioscin ameliorates murine ulcerative colitis by regulating macrophage polarization. Pharmacol Res. 2021; 172:105796. DOI: 10.1016/j.phrs.2021.105796. View

11.

Xiong K, Deng J, Yue T, Hu W, Zeng X, Yang T . Berberine promotes M2 macrophage polarisation through the IL-4-STAT6 signalling pathway in ulcerative colitis treatment. Heliyon. 2023; 9(3):e14176. PMC: 10009548. DOI: 10.1016/j.heliyon.2023.e14176. View

12.

Lv Q, Xing Y, Liu Y, Chen Q, Xu J, Hu L . Didymin switches M1-like toward M2-like macrophage to ameliorate ulcerative colitis via fatty acid oxidation. Pharmacol Res. 2021; 169:105613. DOI: 10.1016/j.phrs.2021.105613. View

13.

Atreya R, Billmeier U, Rath T, Mudter J, Vieth M, Neumann H . First case report of exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy. World J Gastroenterol. 2015; 21(45):12963-9. PMC: 4671048. DOI: 10.3748/wjg.v21.i45.12963. View

14.

Wang J, Wu Z, Huang Y, Jin L, Xu J, Yao Z . IRF4 induces M1 macrophage polarization and aggravates ulcerative colitis progression by the Bcl6-dependent STAT3 pathway. Environ Toxicol. 2024; 39(4):2390-2404. DOI: 10.1002/tox.24106. View

15.

Sadeghi N, Mansoori A, Shayesteh A, Hashemi S . The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis. Phytother Res. 2019; 34(5):1123-1133. DOI: 10.1002/ptr.6581. View

16.

Manzini R, Schwarzfischer M, Atrott K, Laimbacher A, Lang S, Wawrzyniak M . Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis. Inflamm Bowel Dis. 2021; 27(12):1986-1998. DOI: 10.1093/ibd/izab063. View

17.

Choi J, Kim K, Lau L . The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6. Mucosal Immunol. 2015; 8(6):1285-96. PMC: 4583322. DOI: 10.1038/mi.2015.19. View

18.

Horn F, Henze C, Heidrich K . Interleukin-6 signal transduction and lymphocyte function. Immunobiology. 2000; 202(2):151-67. DOI: 10.1016/S0171-2985(00)80061-3. View

19.

Schreiber S, Aden K, Bernardes J, Conrad C, Tran F, Hoper H . Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease. Gastroenterology. 2021; 160(7):2354-2366.e11. DOI: 10.1053/j.gastro.2021.02.062. View

20.

Shahini A, Shahini A . Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiome. J Cell Commun Signal. 2022; 17(1):55-74. PMC: 10030733. DOI: 10.1007/s12079-022-00695-x. View